Serum lipid-bound sialic acid as a marker in breast cancer

Dnistrian, Ann M.; Schwartz, Morton K.; Katopodis, Nonda; Fracchia, Alfred A.; Stock, C. Chester

doi:10.1002/1097-0142(19821101)50:9<1815::aid-cncr2820500927>3.0.co;2-h

Cited by 62 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-associated sialic acid (LASA) content has been studied in patients with various malignancies, including breast cancer. Experimental evidence indicates changes particularly in cells undergoing neoplastic transformation, suggesting LASA determination as a potential marker [17] which might be helpful in the differentiating diagnosis of breast carcinoma in women bearing mammary tumours [18,19]. Despite these results, a role for sialoglycolipids (gangliosides) as markers in cancer is still debated [20].…”

Section: Introductioncontrasting

confidence: 64%

Lipid-associated sialic acid levels in human breast cyst fluids

Mannello

Bocchiotti

Troccoli

et al. 1992

Breast Cancer Res Tr

View full text Add to dashboard Cite

Benign mammary gross cystic disease is the most common breast lesion. Women with apocrine changes of epithelium lining the cysts are at higher risk for developing breast cancer than the normal female population. Sialic acid has drawn considerable interest because of carbohydrate aberrations in malignant cells. The current investigation determined the concentrations of lipid-associated sialic acid (LASA) in 62 breast cyst fluids and sera. Data analyses show a significant increase in the mean values of LASA in metabolically active apocrine cysts when compared to the cysts with Na+/K+ > 3 (flattened cysts) (p < 0.001). The greater LASA levels in cyst fluids with lower intracystic Na+/K+ ratios could represent an altered expression of biosynthetic activity of the surrounding apocrine cell surface sialoglycolipid metabolism, providing a possible explanation of why women with apocrine cysts may be at greater cancer risk and being useful in further studies on functional stage changes in the cysts and their relationship to breast cancer.

show abstract

Section: Introductioncontrasting

confidence: 64%

Lipid-associated sialic acid levels in human breast cyst fluids

Mannello

Bocchiotti

Troccoli

et al. 1992

Breast Cancer Res Tr

View full text Add to dashboard Cite

show abstract

“…Specific monoclonal antibodies (mAbs) to these tumor-associated ganglioside antigens have been utilized for diagnosis, 14,15) prediction of the prognosis, 16,17) and detection of residual tumors.…”

Section: Abstract: Apoptosis -Small Cell Lung Cancer -Chemotherapy -mentioning

confidence: 99%

“…[3][4][5][6] Sarcomas, 7) gastric cancers, 8,9) T cell leukemias [10][11][12] and small cell lung cancer (SCLC) cells 13) also express specific gangliosides. Specific monoclonal antibodies (mAbs) to these tumor-associated ganglioside antigens have been utilized for diagnosis, 14,15) prediction of the prognosis, 16,17) and detection of residual tumors. 18) In particular, anti-ganglioside mAbs have been tried for immunotherapy of melanomas 19,20) and neuroblastomas.…”

mentioning

confidence: 99%

An Anti‐GD2 Monoclonal Antibody Enhances Apoptotic Effects of Anti‐cancer Drugs against Small Cell Lung Cancer Cells via JNK (c‐Jun Terminal Kinase) Activation

Yoshida

Kawaguchi

Sato

et al. 2002

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) cell lines specifically express ganglioside GD2, and anti-GD2 monoclonal antibodies (mAbs) caused suppression of cell growth and induced apoptosis of SCLC cells with single use. Here, enhancement of the cytotoxic effects of various anti-cancer drugs with an anti-GD2 mAb was demonstrated. The cytotoxicity of all six drugs examined was markedly enhanced, i.e. 2.4-7.8-fold increase of cell sensitivity in terms of IC 50 . In particular, the combination of cisplatin (CDDP) with an anti-GD2 mAb resulted in prominent enhancement of cytotoxicity even in low-moderate GD2-expressing lines. The anti-GD2 mAb induced weak activation of c-Jun terminal kinase (JNK) in SCLC cells, and all anti-cancer drugs also induced its activation to various degrees. When CDDP and an anti-GD2 mAb were used together, significantly stronger JNK activation was observed corresponding to the cytotoxic effects, suggesting that synergistic phosphorylation of JNK with two reagents induced prominent apoptosis. The essential role of JNK in the induction of SCLC apoptosis with CDDP and anti-GD2 mAb was confirmed by experiments with a JNK inhibitor, curcumin. These results suggest that anti-GD2 mAbs would be very efficient in combination with anti-cancer drugs, both to achieve SCLC-specific cytotoxicity and to enhance its magnitude. Key words: Apoptosis -Small cell lung cancer -Chemotherapy -JNK -GD2Gangliosides are enriched in nervous tissues of vertebrates 1) and their expression is spatio-temporally regulated.2) In human malignant tumor cells, neuroectodermderived tumor cells such as melanomas, neuroblastomas, and gliomas frequently express characteristic gangliosides for individual tumor types.3-6) Sarcomas, 7) gastric cancers, 8,9) T cell leukemias [10][11][12] and small cell lung cancer (SCLC) cells 13) also express specific gangliosides. Specific monoclonal antibodies (mAbs) to these tumor-associated ganglioside antigens have been utilized for diagnosis, 14,15) prediction of the prognosis, 16,17) and detection of residual tumors.18) In particular, anti-ganglioside mAbs have been tried for immunotherapy of melanomas 19,20) and neuroblastomas. 21)During the early stage of mAb application, anti-GD3 mAb R24 was used for the first time in the treatment of recurrent melanomas, and showed the ability to reduce the tumor size or halt the progression.19) Anti-GD2 mAb was also applied in the treatment of neuroblastomas to extend remission.22) Moreover, a human mAb reactive with GD2 was tried for cutaneous melanomas with some effects. 20)However, further development of antibody therapy has not been successful mainly due to xenogeneic immunogenicity of mouse antibodies and poor penetration of antibodies into tumor tissues.Recently, application of mAbs for the treatment of various cancers has been re-evaluated based on the progress in recombinant molecular technology and protein engineering with site-directed mutagenesis. Anti-c-erbB2/HER2/neu mAb was used in the therapy of advanced stages of breast cancers 23) and anti-CD20 mAb ...

show abstract

“…The LSA level were calculated by using calibration curve (13)(14)(15)(16)(17). The serum CA 125, CA 15-3, CA 19-9, CEA tumor marker levels were determined in autoanalyzer with chemiluminescent immunoassay method by using commercial kits (Immulite 2000 DPC, LosAngeles, USA) (18).…”

Section: Measurement Of Sa Lsa Tumor Markers and Acute Phase Proteinsmentioning

confidence: 99%